Spain’s Market Access update – Aug’16

Spain’s Market Access update – Aug’16

POLICY 70% of the Region’s debt is in Healthcare: total commercial debt to the regions their suppliers rose in May to 9.431 million euros, of which 6.609 million, ie 70%, corresponds to the health sector. Read the Official Ministry Report. Andalucía uses the Electronic prescription to avoid User Charges. As much as 312,000 people a month have avoided having to pay UC when withdrawing a drug. Read more. Valencia is proposing to introduce Therapeutic Equivalents, which beyond the formal definition, include drugs for the same disease with a similar mode of action. Physicians and academic societies are against them. Read more. INDUSTRY Bidafarma is the new wholesaler giant in Andalucía. Read more. Almirall deepens into dermatologic care. It has in-licenced a patent pro Psoriasis. Read the post. DRUGS: Valencia is proposing a network to evaluate and select drugs to be applied across the region. Read more Supreme Court obliges Andalusia to return the compulsory discounts made when naming drugs as Hospital Only. Andalusia has been designating some drugs as HO, entailing them to a compulsory discount. The Supreme Court has ruled that the Region cannot decide which drugs are HO on their own and therefore obliges them to return those discounts to companies. Drug expenditure rose in June16 5’18% more than the previous period last year. New reference groups created 26 new RG have been created, 6 less than the expected There is a RG for vaccines for Varicella, that have been very controversial in the last 2 years. 126 M€ is the estimated impact of these groups. DEVICES: Spanish Agency for Medicines and Health Products (AEMPS) puts in...